Unlike plant extraction or biosynthetic approaches, our process is:
Our platform enables pharmaceutical-grade ligand production with precision, consistency, and environmental responsibility.
Our process begins with limonene, an abundant, low-cost industrial feedstock derived from orange peels.
Through a proprietary catalytic sequence, limonene is converted into a stable, air-tolerant molecular precursor protected by multiple patents.
This precursor forms the foundation of our platform.
Our process delivers:
Catalysts and solvents are recovered, recycled, or reused through standard lifecycle management protocols, reinforcing our green chemistry approach.
Our process is fast and efficient while retaining high purity, single-component end products which have been demonstrated at scale under cGMP conditions. The process has been approved by Health Canada and is fully scalable to multi-ton outputs.
Kare’s catalytic approach provides a more efficient & reliable solution
Production of diverse CB1- and CB2-targeting molecules from a single precursor backbone.
Fine adjustment of molecular architecture to modulate receptor binding profiles.
Development of structurally optimized ligands beyond naturally occurring scaffolds.
Deuterated and carbon-labeled compounds for research and clinical development.
Green chemistry is built into our process design:
Waste feedstock starting material
Catalytic (not stoichiometric) transformations
Solvent recovery and reuse
Low-energy synthetic cycles
Our goal is to make advanced therapeutics without compromising environmental responsibility.
A scalable, industrialized, and defensible platform for the synthesis of high-purity CB1 and CB2 ligands, capable of supporting both B2B pharmaceutical supply and internal drug development.
